Improving the light exposure of office workers Not Applicable
Conditions
Interventions
Current intervention as of 08/03/2022:
Randomisation/allocation: sequence generation
The researchers will perform the assignment of individuals to treatment groups and
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 08/03/2022: 1. Aged 25-45 years 2. Healthy 3. Office worker (work sitting at a desk indoors for the working day) 4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September/October/November/December 2021 5. Working within the Oxford Ring Road, full-time (“9-5”, Monday-Friday), in August/September/October/November/December 2021 6. Android/iOS smartphone user (with a consistent internet connection indoors and outdoors) 7. Able to read and understand English Previous participant inclusion criteria as of 07/10/2021: 1. Aged 25-45 years 2. Healthy 3. Office worker (work sitting at a desk indoors for the working day) 4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September/October/November 2021 5. Working within the Oxford Ring Road, full-time (“9-5”, Monday-Friday), in August/September/October/November 2021 6. Smartphone user (with a consistent internet connection indoors and outdoors) 7. Able to read and understand English Previous participant inclusion criteria: 1. Aged 25-45 years 2. Healthy 3. Office worker (work sitting at a desk indoors for working day) 4. Living within the Oxford Ring Road, full-time (Monday-Sunday), in August/September 2021 5. Working within the Oxford Ring Road, full-time (“9-5”, Monday-Friday), in August/September 2021 6. Working from home, full-time (“9-5”, Monday-Friday), in August/September 2021 7. Android smartphone user (with a consistent internet connection indoors and outdoors) 8. Able to read and understand English
Exclusion criteria
Exclusion criteria: Current participant exclusion criteria as of 08/03/2022: 1. Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, PTSD (GAD-7; =10) 2. Major Depression (PHQ-9; =10) 3. Suicidal ideation with intent or attempted suicide within past 2 months 4. Formal diagnosis of a mental health disorder 5. Extreme early and late chronotypes (µMCTQ; =2 or =6) 6. Shift or night worker in the past 3 months 7. Formal diagnosis of a sleep disorder 8. Drug abuse (DAST-10; =3) 9. Alcohol use disorder (AUDIT; =16) 10. Caffeine dependence (SDS; =4) 11. Sleep medication 12. Smoker/vape user 13. Antidepressants (e.g., serotonin reuptake inhibitors) 14. Anxiety medication 15. Photosensitive medication 16. Benzodiazepines or non-benzodiazepine hypnotics 17. Beta/alpha blockers 18. Underweight and obese BMI (less than 18.5 or greater than 29.9 kg/m²) 19. Significant medical or surgical condition 20. Planning major surgery in the next 6 months 21. Significant pain or physical distress 22. Serious head injury in the past year 23. Neurological disorder 24. Neurodevelopmental disorder 25. Physical disability preventing moderate exercise (e.g., going for a 30-min walk) 26. Eye disease 27. Life expectancy <1 year 28. Menopausal 29. Lactating or pregnant 30. Significant recent, or foreseeable life events (death in family, moving to a new house, divorce) 31. Undergone light therapy in the last month/plan to have light therapy within the next 6 months 32. Received/receiving psychological treatment for a sleep disorder 33. Currently taking part in a study involving a drug or behavioural intervention/ will be taking part in such a study in the next 3 months 34. Knowing of someone who is participating/has participated in the data collection aspect of this study Previous participant exclusion criteria as of 07/10/2021: 1. Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, PTSD (GAD-7; =10) 2. Major Depression (PHQ-9; =10) 3. Suicidal ideation with intent or attempted suicide within past 2 months 4. Formal diagnosis of a mental health disorder 5. Extreme early and late chronotypes (µMCTQ; =2 or =6) 6. Shift or night worker in the past 3 months 7. Formal diagnosis of a sleep disorder 8. Drug abuse (DAST-10; =3) 9. Alcohol use disorder (AUDIT; =16) 10. Caffeine dependence (SDS; =4) 11. Sleep medication 12. Smoker/vape user 13. Antidepressants (e.g., serotonin reuptake inhibitors) 14. Anxiety medication 15. Photosensitive medication 16. Benzodiazepines or non-benzodiazepine hypnotics 17. Beta/alpha blockers 18. Underweight and obese BMI (less than 18.5 or greater than 29.9 kg/m²) 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility: 1. Feasibility of the intervention will be measured using an app and quiz and the feasibility section of the custom feasibility and acceptability questionnaire at the end of the trial 2. Feasibility of the design and procedures will be measured using a screening survey, custom allocation/randomisation script consent forms, a follow-up questionnaire, the feasibility section of the custom feasibility and acceptability questionnaire and a self-report question at the end of the trial 3. Feasibility of the design and procedures in terms of completeness will be assessed by calculating the average percentage of daily questionnaires completed with valid data (GoodBarber), the average percentage of repeat questionnaires completed with valid data (REDCap), and the average percentage of actigraphs worn with valid data at the end of the trial (added 20/07/2021) Acceptability: 1. Acceptability of the intervention will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial 2. Acceptability of the placebo will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial 3. Acceptability of the study procedures will be measured using the acceptability section of the custom feasibility and acceptability questionnaire at the end of the trial Sample size calculation: 1. Sample size for a definitive main trial calculated using a non-central t-distribution (NCT) approach at the end of the trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Three secondary outcome domain-specific measures will be assessed | — |
Countries
England, United Kingdom
Outcome results
None listed